Discontinued drugs in 2006: Anti-infectives

Expert Opinion on Investigational Drugs

Volumn 16, Issue 12, 2007, Pages 1867-1878

  Ryder, Neil S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Anti infectives; Coronavirus; Discontinued drugs; HIV; Pseudomonas aeruginosa; Respiratory syncytial virus; SARS virus; Severe acute respiratory syndrome

Indexed keywords

4' AZIDOCYTIDINE; A 33903; A 60444; AERUGEN; ALPHA GLYCINAMIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; BISMUTH 201; BMS 2; BMS 605339; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELVUCITABINE; GR 270773; HEPATITIS C VIRUS PROTEASE INHIBITOR; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; PSEUDOMONAS VACCINE; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SINOVAC; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADD ON THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DENGUE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOSTIMULATION; MONOTHERAPY; NEOPLASM; NONHUMAN; PROTEIN SYNTHESIS; SEPSIS; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE DRUG DOSE; TREATMENT INDICATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VIRUS ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BLOOD; CHEMISTRY; COMMUNICABLE DISEASE; PHARMACEUTICS; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 39549111525     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1867     Document Type: Article

References (6)

1. ANDERSSON E, HORAL P, JEJCIC A et al.: Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide. Antimicrob. Agents Chemother. (2005) 49:40-44.
2. CHAPMAN J, ABBOTT E, ALBER DG et al.: RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. (2007) 51:3346-3353.
3. MOSKOWITZ DW: Is angiotensin I-converting enzyme a "master" disease gene? Diabetes Technol. Ther. (2002) 4:683-711.
4. ZUERCHER AW, HORN MP, QUE JU et al.: Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. (2006) 47:302-308.
5. ANONYMOUS: New antimicrobial agents approved by the US food and drug administration in 2006 and new indications for previously approved agents. Antimicrob. Agents Chemother. (2007) 51:2649.
6. HAN W, JIANG Y, HU Z, WASSERMAN ZR, DECICCO CP: Investigation of glycine α-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres. Bioorg. Med. Chem. Lett. (2005) 15(15):3487-3490.